EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma

Masaharu Oki, Kojiro Ohba, Yuta Mukae, Tsuyoshi Matsuda, Hiromi Nakanishi, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Ryoichi Imamura

In Vivo · 2025

DOI: 10.21873/invivo.14142 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift In Vivo, 2025. Verfasst von Masaharu Oki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Protein Kinase Inhibitors, Immune Checkpoint Inhibitors, Kidney Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellProtein Kinase InhibitorsImmune Checkpoint InhibitorsKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultTreatment OutcomeNeoplasm MetastasisPrognosisTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Immune checkpoint inhibitorfavourable riskrenal cell carcinomatyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsImmune Checkpoint InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Urology and Renal Transplantation, Nagasaki University Hospital, Nagasaki, Japan ohba-k@nagasaki-u.ac.jp.

Zitieren

APA

Oki, M., Ohba, K., Mukae, Y., Matsuda, T., Nakanishi, H., Mitsunari, K., Matsuo, T., Mochizuki, Y., & Imamura, R. (2025). Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma. In Vivo. https://doi.org/10.21873/invivo.14142

Vancouver

Oki M, Ohba K, Mukae Y, Matsuda T, Nakanishi H, Mitsunari K, et al. Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma. In Vivo. 2025. doi:10.21873/invivo.14142

BibTeX
@article{Oki2025,
  author = {Oki, Masaharu and Ohba, Kojiro and Mukae, Yuta and Matsuda, Tsuyoshi and Nakanishi, Hiromi and Mitsunari, Kensuke and Matsuo, Tomohiro and Mochizuki, Yasushi and Imamura, Ryoichi},
  title = {Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.14142}
}
Kostenlos starten →